Actively Recruiting
Feasibility of Early Gabapentin as an Intervention for Neurorecovery
Led by MetroHealth Medical Center · Updated on 2025-12-02
42
Participants Needed
1
Research Sites
233 weeks
Total Duration
On this page
Sponsors
M
MetroHealth Medical Center
Lead Sponsor
N
National Institute on Disability, Independent Living, and Rehabilitation Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.
CONDITIONS
Official Title
Feasibility of Early Gabapentin as an Intervention for Neurorecovery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Traumatic spinal cord injury
- Any level of spinal cord injury
- Injury severity classified as AIS A-D
- Age 18 years or older
- Willing to start study medication within 120 hours after injury
- Able to provide informed consent with adequate cognition and communication
You will not qualify if you...
- Moderate or severe traumatic brain injury with Glasgow Coma Score less than 13 at 120 hours post-injury
- Use of gabapentinoid medications at the time of injury
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
Actively Recruiting
Research Team
M
Mayson Moore
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here